PDCD1 and acute myeloid leukemia: CLL-1 CAR-T cells with PD-1 knockdown show a successful therapy in patients and represent a feasible immunotherapeutic alternative for treating relapsed or refractory AML (Lin et al., 2021; Ma et al., 2022).